摘要
目的探究依洛尤单抗联合马来酸桂哌齐特治疗在冠心病患者中的应用效果。方法回顾性收集郑州大学第五附属医院2021年12月至2023年10月收治的125例冠心病患者的临床资料,根据治疗方案分为单药组(n=63)和联合组(n=62)。单药组给予马来酸桂哌齐特治疗,联合组给予依洛尤单抗联合马来酸桂哌齐特治疗,对比两组的疗效、心功能[心脏指数(cardiac index,CI)、心排血量(cardiac output,CO)、E峰流速/A峰流速(E/A)]、凝血功能[凝血酶原时间(prothrombin time,PT)、活化部分凝血活酶时间(activated partial thromboplastin time,APTT)、纤维蛋白原(fibrinogen,FIB)]及血清因子[肿瘤坏死因子相关蛋白9(complement Clq tumor necrosis factor-related protein 9,CTRP9)、组织蛋白酶(cathepsin S,Cat S)、可溶性核因子-κB受体活化因子配体(soluble receptor activator of nuclear factor-κB ligand,sRANKL)、转化生长因子结合蛋白2(latent TGF-βbinding protein 2,LTBP-2)]水平和不良反应发生率。结果治疗后,联合组的总有效90.48%高于单药组76.19%(P<0.05);联合组的CI,CO,E/A高于单药组(P<0.05);联合组的APTT,PT水平高于单药组,FIB水平低于单药组(P<0.05);联合组的Cat S,sRANKL,CTRP9水平高于单药组,LTBP-2水平低于单药组(P<0.05)。结论依洛尤单抗联合马来酸桂哌齐特治疗冠心病患者疗效确切,可改善心功能,增强凝血功能,减轻机体炎性反应,较安全可靠。
Objective To explore the efficacy of evolocumab combined with cinepazide maleate in the treatment of patients with coronary heart disease.Methods Clinical data of 125 patients with coronary heart disease in the Fifth Affiliated Hospital of Zhengzhou University from December 2021 to October 2023 were retrospectively collected and divided into single drug group(n=63)and combination group(n=62)according to treatment plan.The single drug group was treated with cinepazide maleate,and the combination group was treated with evolocumab+cinepazide maleate.The therapeutic effect,cardiac function[cardiac index(CI),cardiac output(CO),peak E/peak A velocity(E/A)],coagulation function[prothrombin time(PT),activated partial thromboplastin time(APTT),fibrinogen(FIB)],complement Clq tumor necrosis factorrelated protein 9(CTRP9)and cathepsin(S),soluble receptor activator of nuclear factor-κB ligand(sRANKL),latent TGF-βbinding protein2(LTBP-2)levels,and incidence of adverse reactions were compared between the two groups.Results The total effective rate of combination group was 90.48%higher than that of single drug group 76.19%(P<0.05).After treatment,CI,CO and E/A in combination group were higher than those in Single drug group(P<0.05).After treatment,APTT and PT in combination group were higher than Single drug group,FIB was lower than single drug group(P<0.05).After treatment,cathepsin S,sRANKL and CTRP9 were higher and LTBP-2 lower in the combination group than in the Single drug group(P<0.05).Conclusion Evolocumab combined with cinepazide maleate is effective in the treatment of patients with coronary heart disease.It can improve cardiac function,enhance coagulation function,reduce inflammatory reaction,and is safe and reliable.
作者
郭晓亮
沈航
GUO Xiao-liang;SHEN Hang(Department of Cardiology,the Fifth Affiliated Hospital of Zhengzhou University,Henan 450052,China;不详)
出处
《慢性病学杂志》
2024年第4期498-501,共4页
Chronic Pathematology Journal
基金
河南省医学科技攻关计划(联合共建)项目[心肺运动试验制定个体化运动康复处方治疗老年高血压的疗效研究](LHGJ20190415)
关键词
冠心病
依洛尤单抗
马来酸桂哌齐特
凝血功能
Coronary heart disease
Evolocumab
Cinepazide maleate
Coagulation function
作者简介
通信作者:郭晓亮,硕士研究生,主治医师,研究方向:心血管内科药物及介入治疗,E-mail:g198502@163.com
